Endotoxemia and its association with immune and coagulopathy responses in severe community-acquired pneumonia and COVID-19.

Date publication

mars 2026

Journal

Intensive care medicine experimental

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BINQUET Christine , Dr PAIS DE BARROS Jean-Paul , Pr MASSON David

Tous les auteurs :
Blot M, Sow AK, Masson D, Nguyen M, Jacquier M, Pais de Barros JP, Sixt T, Luu M, Charles PE, Piroth L, Quenot JP, Binquet C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41796408

Résumé

Acute community-acquired pneumonia (CAP) is a leading cause of infection-related mortality worldwide. Endotoxemia, characterized by elevated plasma lipopolysaccharide (LPS), is a key driver of inflammation and thrombosis in Gram-negative sepsis and has been suggested to occur in severe pneumonia, irrespective of etiology. However, current immunoassays for LPS quantification lack sensitivity and specificity. We aimed to quantify plasma LPS in severe CAP patients, including COVID-19, using a validated mass spectrometry method, and to explore associations with immune activation, coagulation, gut translocation, and clinical outcomes.

Mots clés

Cardiovascular event, Coagulopathy, Community-acquired pneumonia, Endotoxemia, Immune response, Lipopolysaccharide, Mortality, Thrombosis

Référence

Intensive Care Med Exp. 2026 03 9;14(1):